nafamostat has been researched along with Cardiac Failure in 4 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| "We concluded that platelet-activating factor may play a critical role in the development of severe heart failure with left ventricular assistance, and nafamostat administration is likely to be beneficial in such a critical condition by suppressing the platelet-activating factor level." | 7.70 | Nafamostat mesilate modulates the release of platelet-activating factor during left ventricular assistance with hemofiltration in canine heart failure. ( Fukui, K; Koyama, M; Munakata, M; Ono, Y; Satoh, K; Suzuki, S, 2000) |
| "We concluded that platelet-activating factor may play a critical role in the development of severe heart failure with left ventricular assistance, and nafamostat administration is likely to be beneficial in such a critical condition by suppressing the platelet-activating factor level." | 3.70 | Nafamostat mesilate modulates the release of platelet-activating factor during left ventricular assistance with hemofiltration in canine heart failure. ( Fukui, K; Koyama, M; Munakata, M; Ono, Y; Satoh, K; Suzuki, S, 2000) |
| " We investigated the ideal dosage and efficacy of nafamostat mesilate for use with ECMO in patients with acute cardiac or respiratory failure." | 1.37 | Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. ( Han, SJ; Hong, KS; Kim, HS; Kim, KI; Lee, SH; Lee, WK; Whang, SM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, SJ | 1 |
| Kim, HS | 1 |
| Kim, KI | 1 |
| Whang, SM | 1 |
| Hong, KS | 1 |
| Lee, WK | 1 |
| Lee, SH | 1 |
| Sawaki, D | 1 |
| Otani, Y | 1 |
| Kobayakawa, N | 1 |
| Sekita, G | 1 |
| Fukushima, K | 1 |
| Takeuchi, H | 1 |
| Ogawa, T | 1 |
| Takemura, T | 1 |
| Aoyagi, T | 1 |
| Ihno, T | 1 |
| Nakagawa, T | 1 |
| Furukawa, H | 1 |
| Shimizu, K | 1 |
| Egi, K | 1 |
| Maemura, T | 1 |
| Motomiya, T | 1 |
| Munakata, M | 1 |
| Ono, Y | 1 |
| Koyama, M | 1 |
| Fukui, K | 1 |
| Satoh, K | 1 |
| Suzuki, S | 1 |
4 other studies available for nafamostat and Cardiac Failure
| Article | Year |
|---|---|
Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.
Topics: Acute Disease; Anticoagulants; Benzamidines; Dose-Response Relationship, Drug; Extracorporeal Membra | 2011 |
A case of heparin-induced thrombocytopenia with sepsis and congestive heart failure--first autopsy report on Japan--.
Topics: Aged; Aged, 80 and over; Antibodies; Benzamidines; Enzyme-Linked Immunosorbent Assay; Fatal Outcome; | 2004 |
Various problems during long-term percutaneous cardiopulmonary support.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Benzamidines; Blood Transfusion, Autologous; Cardiop | 1997 |
Nafamostat mesilate modulates the release of platelet-activating factor during left ventricular assistance with hemofiltration in canine heart failure.
Topics: Animals; Antithrombins; Benzamidines; Dogs; Guanidines; Heart Failure; Heart-Assist Devices; Hemofil | 2000 |